
Jacob Bell
Senior Reporter | @realjacobbellJacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
1521 articles by Jacob Bell
-
European regulators want to know more about the risks of GLP-1 drugs
Dec. 1, 2023 -
Bristol Myers pours $100M into RNA drugs for cardiovascular diseases
Nov. 28, 2023 -
Xenon drug misses main goal of depression study
Nov. 27, 2023 -
AstraZeneca creates digital health unit, with big-name partnerships already in place
Nov. 20, 2023 -
Biogen says growth is coming, but won’t specify when
Nov. 8, 2023 -
A brain-focused biotech raises $225M to develop drugs for schizophrenia, Parkinson’s
Oct. 30, 2023 -
Bristol Myers’ neuroscience research head explains the big pharma’s return to brain drugs
Oct. 27, 2023 -
Vertex gearing up for launch as sickle cell therapy review advances
Oct. 26, 2023 -
Eisai says new data could support more convenient form of Alzheimer’s drug Leqembi
Oct. 25, 2023 -
BrainStorm, after setbacks, withdraws approval application for ALS drug
Oct. 18, 2023 -
Roche is stuck on molecular glue
Oct. 17, 2023 -
Amylyx’s ALS drug knocked back again in Europe
Oct. 13, 2023 -
After summer slump, biotech M&A has a good week
Oct. 10, 2023 -
NIH funds research for three experimental ALS drugs
Oct. 6, 2023 -
AbbVie acquires Parkinson’s drug in latest biotech buyout
Oct. 5, 2023 -
Regeneron, Intellia target neurological diseases in expanded gene editing deal
Oct. 3, 2023 -
Novartis’ closely watched rare disease drug scores in kidney disorder
Oct. 2, 2023 -
Seagen’s cancer drug succeeds in ‘must-win’ trial
Sept. 22, 2023 -
FDA approves GSK’s new bone cancer drug, helping validate a billion-dollar bet
Sept. 18, 2023 -
New startup Arialys takes aim at the immune system, hoping to create neuropsychiatry drugs
Sept. 12, 2023 -
Alnylam says hypertension drug succeeded in mid-stage study
Sept. 7, 2023 -
Biogen, continuing executive revamp, finds a new research head
Sept. 6, 2023 -
FDA documents hint at ‘uphill battle’ for broad approval of Sage’s depression drug
Sept. 1, 2023 -
Sanofi appoints a venture investor to R&D head as executive team expands
Aug. 31, 2023 -
Bayer reports positive early data for Parkinson’s cell therapy
Aug. 28, 2023